Malaria
Conditions
Interventions
Artemether lumefantrine
Artemether lumefantrine plus single dose primaquine
Sponsors
University of Bergen
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Aged =15 Fever (body temperature =37.5 °C) or history of fever in the last 24 hr Microscopically confirmed P. falciparum mono-infections The parasitemia ranges from 1000 to 100000 per microliter of asexual forms Willingness to abide by the study protocol Ability to swallow oral treatment Ready for follow-up visits and provided written informed consent/assent before enrolment
Exclusion criteria
Exclusion criteria: Severe malaria or danger signs Known allergy to artemether-lumefantrine or primaquine Those who take anti-malarial drugs or drugs with anti-malarial properties within 2 weeks Pregnant (self-reported) Breastfeeding women The presence of febrile conditions caused by diseases other than malaria Known serious or chronic medical conditions (e.g., cardiac, renal, hepatic diseases, sickle cell disease, HIV/AIDS)(self-reported) Taking regular medication, which may interfere with artemether-lumefantrine and primaquine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of P. falciparum cases with parasitological responses in the artemether-lumefantrine plus primaquine group compared with the artemether-lumefantrine group using microscopy. The proportion of patients with gametocytes at baseline and subsequent follow-up days using microscopy. | — |
Secondary
| Measure | Time frame |
|---|---|
| The number of P. falciparum cases with reinfection and recrudescence at the later stage of follow-up The proportion of patients with negative PCR result in the artemether-lumefantrine plus primaquine group compared with the artemether-lumefantrine group | — |
Countries
Ethiopia
Contacts
Public ContactSamson Tizazu
Ass.Prof.Industrial and Environmental Biotechnology
Outcome results
None listed